Eyeworld

WINTER 2024

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1529000

Contents of this Issue

Navigation

Page 75 of 94

WINTER 2024 | EYEWORLD | 73 G EVOLVING by Liz Hillman Editorial Co-Director About the physicians Shakeel Shareef, MD Director, The Center for Glaucoma & Cataract Care Chief of the Ophthalmology Section, Department of Surgery HCA Reston Hospital Center Reston, Virginia Benjamin Y. Xu, MD, PhD Associate Professor of Clinical Ophthalmology Chief of the Glaucoma Service Director of Data Science and Artificial Intelligence USC Roski Eye Institute Keck School of Medicine Los Angeles, California closure glaucoma differ, so to misclassify a pa- tient means you may not be offering the optimal or ideal treatments," he said. In the Lee et al. study, Dr. Xu, who was the corresponding author, said patients with an open angle diagnosis were 10 times less likely to have a gonioscopy compared to angle closure glaucoma. If patients are not receiving gonioscopy, they're less likely to be diagnosed with angle closure. "Angle closure glaucoma is a very treatable and preventable form of glaucoma early on. You can provide laser and surgery and effectively eliminate the risk of glaucoma, whereas if you presume the patient has open angle glaucoma and treat with eye drops alone, the angle closure can worsen and become difficult to control," Dr. Xu said. "My general advice is to still perform gonioscopy in all patients receiving glaucoma evaluations be- cause it provides valuable information to guide management." He also pointed out that gonioscopy can reveal other abnormalities in the angle, such as neovascularization and iris or ciliary body tumors. "These are devastating to miss early on. In the absence of a more convenient assessment like OCT … we should still continue to perform gonioscopy so we can provide our patients with the standard of care," Dr. Xu said. I n August 2024, Lee et al. published a paper that looked at nearly 200,000 initial glaucoma evaluations, finding that 20.4% and 29.5% had a gonioscopy performed on the day of diagnosis or within 6 months of their evaluation, respectively. 1 Statistics like this might prompt questions like, "Is gonioscopy dead?" While glaucoma specialists who spoke with EyeWorld said gonioscopy remains a vital and valuable tool in the clinic, newer imaging systems can help visualize the angle as well, overcoming some limitations of gonioscopy and becoming a complementary technology. "Office-based gonioscopy is alive and well. It forms an integral part of an eye exam … but [is] unfortunately underutilized in clinical prac- tice," said Shakeel Shareef, MD. Benjamin Y. Xu, MD, PhD, said he could see how someone who performs gonioscopy regularly, experiencing its limitations frequently, might ask whether gonioscopy is dead or still necessary. He assures those in the field that it still has a place. Why office-based gonioscopy remains important Dr. Xu said gonioscopy remains important for patients having glaucoma evaluations. "The management of open angle glaucoma and angle Is gonioscopy dead? continued on page 74 High-resolution cross-sectional image, nasal to temporal; note appositional angle closure of iris scroll abutting the angle structures (red arrow) and the slit opening of the angle (right side) with a 4-degree inlet Source: Shakeel Shareef, MD

Articles in this issue

Archives of this issue

view archives of Eyeworld - WINTER 2024